Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $4.04B
• Dividend Yield: N/A
• Average Volume (3M): 308.59K
• Price to Earnings (P/E): 18.9
• Beta (1Y): 0.41
• Revenue Growth: 1.10%
• EPS Growth: 2.65%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Distribution
• EPS (TTM): 1.32
• Shares Outstanding: 49,414,707
• 10 Day Avg. Volume: 307,475
• 30 Day Avg. Volume: 308,590
• PEG Ratio: 0.27
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.08
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 0.99
• Enterprise Value/Gross Profit: 6.99
• Enterprise Value/Ebitda: 3.11
• 1Y Price Target: $85.00
• Price Target Upside: 4.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 69 Neutral
• Price Target: $90.00 ▲(10.91%Upside)

The overall stock score reflects strong financial performance and positive earnings guidance. However, technical analysis indicates bearish momentum, and moderate valuation limits the upside potential. The lack of a dividend yield might deter some investors.

Positive Factors

Debt Management

Prestige has significantly reduced its debt, offering flexibility for further debt reduction, share buybacks, or engaging in profitable acquisitions.

Earnings

PBH reported strong results with sales beating guidance, driven by international and North American strength.

Management Strategy

PBH is highlighted as a focus stock due to its niche brand portfolio of need-based brands helping insulate against macro pressure and strong management execution on brand-building.

Negative Factors

Leadership Changes

The appointment to a dual CFO/COO role could indicate PBH is looking closely at M&A and wants additional oversight on integrating any acquisition.

Market Position

PBH did not previously have a Chief Operating Officer, and the new role is seen as a natural progression for operational duties and oversight.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

How the Company Makes Money

Prestige Consumer Healthcare makes money by developing and selling a diverse portfolio of over-the-counter healthcare products. The company's revenue model primarily relies on the sales of these products through various distribution channels, including pharmacies, supermarkets, and online retailers. Key revenue streams include the sale of branded products in categories such as pain relief, gastrointestinal health, and eye care. Prestige Consumer Healthcare benefits from strategic partnerships with retailers and distributors to maximize market reach and increase product availability. The company's earnings are also influenced by factors such as consumer demand for self-care products, brand recognition, and effective marketing strategies.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Prestige Consumer Healthcare demonstrates solid financial health across income, balance sheet, and cash flow metrics. The company shows consistent revenue growth and strong profitability margins, while maintaining a low leverage position. Cash flow generation is stable, supporting operational and financial flexibility. Overall, the company's financial statements reflect a well-managed business with potential for continued growth and profitability.

Income Statement

Prestige Consumer Healthcare has shown consistent revenue growth, with a 1.1% increase from 2024 to 2025. The gross profit margin remains strong at 55.8% in 2025, reflecting effective cost management. However, the EBIT margin slightly decreased from 30.4% in 2024 to 29.6% in 2025, indicating some pressure on operational efficiency. The net profit margin improved slightly to 18.9% in 2025, highlighting enhanced profitability.

Balance Sheet

The company's financial stability is solid with a low debt-to-equity ratio of 0.03 in 2025, demonstrating effective debt management. The equity ratio is strong at 53.9%, indicating a healthy proportion of equity financing. Return on equity stands at 11.7%, showing reasonable profitability for shareholders. The improvement in equity and reduction in total liabilities over the years reflect a strengthening balance sheet.

Cash Flow

Operating cash flow increased slightly to $251.5 million in 2025, supporting ongoing operations effectively. Free cash flow growth is modest at 1.6% year-over-year, but the free cash flow to net income ratio is robust at 1.13, indicating strong cash generation relative to profits. The stable cash flow trends suggest efficient cash management and operational stability.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	353.11M	373.86M	14.19M	351.61M	310.38M
Net Income	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	51.89M	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 81.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Negative. The current price of 81.15 is below the 20-day moving average (MA) of 84.39, below the 50-day MA of 83.93, and above the 200-day MA of 80.37, indicating a neutral trend. The MACD of -0.59 indicates Positive momentum. The RSI at 35.93 is Neutral, neither overbought nor oversold. The STOCH value of 26.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSIC	71 Outperform	$8.86B	22.63	11.78%	―	1.75%	8.76%
PDCO	70 Outperform	$2.77B	20.21	14.15%	2.49%	-0.85%	-23.40%
CAH	70 Outperform	$39.08B	25.57	-43.80%	1.24%	0.78%	183.45%
PBH	69 Neutral	$4.04B	18.93	12.30%	―	1.10%	2.65%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
OMI	51 Neutral	$638.20M	―	-49.91%	―	2.84%	-828.91%
GRDN	47 Neutral	$1.31B	―		―	―	―

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare Reports Record Fiscal Year Revenue

On May 8, 2025, Prestige Consumer Healthcare reported record revenue and earnings for the fiscal year ending March 31, 2025, with a revenue of $1,137.8 million and a diluted EPS of $4.29. The company saw significant growth in its international business and North American categories, particularly in gastrointestinal and women’s health, and achieved a strong free cash flow, which facilitated share repurchases and debt reduction. Looking ahead to fiscal 2026, Prestige anticipates organic revenue growth of 1% to 2% and EPS growth, despite inflationary challenges, leveraging its diverse product portfolio and agile operating model to maintain consistent financial performance and shareholder value.